Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?

Executive Summary

As expected, Intercept Pharmaceuticals Inc. was granted an accelerated approval for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis. But the drug's potential in the much more lucrative indication of nonalcoholic steatohepatitis may be what piques the interests of larger pharmaceutical companies for a possible acquisition of the New York-based biotech.

Advertisement

Related Content

The NASH Pipeline: Replete With Targets And New Compounds
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Positive Panel, But What's Ahead For Intercept's Ocaliva?
'Boring' Bodes Well For Future Of Intercept's Ocaliva

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel